Rho GTPase-Activating Protein 35 rs1052667 Polymorphism and Osteosarcoma Risk and Prognosis
Figure 1
Association between ARHGAP35 rs1052667 polymorphism and osteosarcoma prognosis in 247 osteosarcoma patients. ARHGAP35 rs1052667 polymorphism was correlated with (a) the overall survival and (b) the recurrence-free survival of osteosarcoma. Cumulative hazard function was plotted by the Kaplan-Meier methodology and the value was calculated with two-sided log-rank tests. MST, the median overall survival time; MRT, the median tumor recurrence-free survival time.